BeyondSpring (BYSI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for September 15, 2025, at 9:00 AM ET at 100 Campus Drive, Florham Park, NJ.
Shareholders can vote in person or electronically using a 12-digit control number.
Proxy materials, including the proxy statement and card, are available online for review and download.
Voting matters and shareholder proposals
Proposal to ratify the appointment of CBIZ CPAS P.C. as independent registered public accounting firm for fiscal year ending December 31, 2025.
Board recommends a vote "FOR" the ratification of the auditor.
Other matters may be addressed as properly brought before the meeting or any adjournment.
Audit committee and external auditor matters
Ratification of CBIZ CPAS P.C. as the independent auditor for the upcoming fiscal year is up for shareholder vote.
Latest events from BeyondSpring
- Plinabulin achieved Phase 3 survival benefit in NSCLC; financials strengthened and pipeline advanced.BYSI
Q4 202525 Mar 2026 - Biopharma firm registers 10M shares for R&D and corporate use, facing clinical and financial risks.BYSI
Registration Filing16 Dec 2025 - Up to 10M shares registered for flexible sale to fund R&D amid ongoing financial uncertainty.BYSI
Registration Filing16 Dec 2025 - Shareholders will vote to ratify CBIZ as auditor at the September 2025 AGM.BYSI
Proxy Filing2 Dec 2025 - Net loss narrowed, Plinabulin advanced in NSCLC, SEED divested and raised $30M, cash at $12.5M.BYSI
Q3 202512 Nov 2025 - Q2 2025 saw narrowed net loss, SEED divestiture progress, and clinical advances in oncology.BYSI
Q2 202513 Aug 2025 - Plinabulin and SEED's TPD platform deliver clinical and pipeline breakthroughs with strong pharma alliances.BYSI
Corporate Presentation4 Jul 2025 - Net loss narrowed and cash improved, but shareholder's deficit remains substantial.BYSI
Q2 202413 Jun 2025 - Q1 2025 net income rose to $4.5M from SEED sale; Plinabulin advanced in cancer trials.BYSI
Q1 20256 Jun 2025